Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call
2019年8月9日 - 3:16AM
Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases, yesterday reviewed recent market
research based on in-depth interviews (n=44)1 and quantitative
surveys (n=1,504)2 of patients and physicians, showing the unmet
need amongst lactose intolerance (LI) sufferers and interest in new
treatment options from both patients’ and physicians’ perspectives.
The call was hosted by Andrew J. Ritter, Ritter Pharmaceuticals’
CEO, and Daniel P. Lundberg, Founder and former Chief Marketing
Officer at Vivelix Pharmaceuticals and former Senior VP of
Marketing at Salix Pharmaceuticals.
An archive of the call can be accessed here and
on RitterPharma.com (Investors – Events & Presentations
page).
Highlights from the call include the
following:
- Identification of a target market
for RP-G28 – LI patients with moderate to severe symptoms,
estimated at 30% of the LI population (or 15 million in the United
States and 17 million in Europe).3
- Discussion of unmet needs,
especially for moderate-severe LI patients, where current treatment
options do not sufficiently address symptoms, require high
compliance, and/or are undesirable to follow. Further, while most
patients report attempting to reduce or avoid dairy as their first
defense against LI symptoms, dairy avoidance was found to be
challenging and undesirable by LI sufferers as 92% of LI sufferers
would like to eat some dairy and 66% of LI sufferers find it
difficult to avoid dairy.2 Physicians also recognize the
limitations of current treatment options and the compliance
challenges required to avoid symptoms.
- Overview of interest in RP-G28 –
physicians interviewed were interested in prescribing RP-G28 and
estimate about half of their LI patients would be suitable for a
prescription, while some gastroenterologists (GI) managing a higher
volume of severe LI patients, indicated they would potentially
recommend RP-G28 to 2 out of 3 of their LI patients.1 In addition,
56% of the LI population surveyed, and 60% of the moderate-severe
LI sufferers, indicated interest in RP-G28.2
- Review of preliminary go-to-market
strategy to include both traditional physician engagement,
especially gastroenterologists who primarily diagnose and manage
the moderate-severe patients, and evolving methods of engagement
via social media and online targeted ads.
“Ritter, with RP-G28, has an opportunity to
disrupt how lactose intolerance is being managed, first by
providing a safe, effective therapeutic, but also by leveraging the
evolution of how care is being delivered,” said Mr. Lundberg.
“Ritter should be able to plan for a focused and efficient
go-to-market strategy, combining both a small-to-moderately sized
GI-focused specialty field force, supplemented by a smart and
targeted social media and digital marketing campaign.”
In July 2019, the Company announced the
completion of the “last patient last visit” for the Phase 3 trial
of RP-G28 for the potential treatment of LI, a study known as
“Liberatus.” Ritter Pharmaceuticals is on track to announce topline
results of the Liberatus trial in early Q4 2019.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc.
(www.ritterpharma.com, @RitterPharma) develops innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases. The Company’s lead product candidate,
RP-G28, has the potential to become the first FDA-approved
treatment for lactose intolerance, a condition that affects
millions worldwide. RP-G28 is in Phase 3 clinical development with
its first Phase 3 clinical trial, known as “Liberatus,” currently
in its finalization stage with top-line data expected in early Q4
2019. The Company is further exploring the therapeutic potential
that gut microbiome changes may have on treating/preventing a
variety of diseases including gastrointestinal diseases, cancer,
metabolic, and liver disease.
Forward-Looking Statements
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that express the current beliefs and
expectations of Ritter Pharmaceuticals’ management. Any statements
contained herein that do not describe historical facts, including
statements related to our anticipated timing for the release of
data from our Liberatus clinical trial and potential lactose
intolerance market opportunity forecasts, are forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from those discussed in such
forward-looking statements. Some of the factors that could affect
our actual results are included in the periodic reports on Form
10-K and Form 10-Q that we file with the Securities and Exchange
Commission. Ritter cautions readers not to place undue reliance on
any forward-looking statements, which speak only as of the date
they were made. The Company undertakes no obligation to update or
revise forward-looking statements, except as otherwise required by
law, whether as a result of new information, future events or
otherwise.
Sources
- Cadence. (2019). Lactose Intolerance Patient Journey
Study.
- JJN Consulting. (2019). Lactose Intolerance & RP-G28
Quantitative Study: Understanding the Universe of Lactose
Intolerant Sufferers.
- Delveinsight. (2019). Lactose Intolerance: Market Insights,
Epidemiology and Market Forecast-2028.
Contacts Investor Contact: John Beck
310-203-1000 John@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024